Title: Effective treatment of ductal carcinoma in situ with a HER-2-targeted alpha-particle emitting radionuclide in a preclinical model of human breast cancer
Authors: YOSHIDA TakahiroJIN KideokSONG H.PARK SunjuHUSO D. L.ZHANG Z.LIANGFENG HanZHU CharlesBRUCHERTSEIFER FrankMORGENSTERN AlfredSGOUROS G.SUKUMAR Saraswati
Citation: ONCOTARGET vol. 7 no. 22 p. 33306-33315
Publisher: IMPACT JOURNALS LLC
Publication Year: 2016
JRC N°: JRC101800
ISSN: 1949-2553
URI: http://publications.jrc.ec.europa.eu/repository/handle/JRC101800
DOI: 10.18632/oncotarget.8949
Type: Articles in periodicals and books
Abstract: The standard treatment for ductal carcinoma in situ (DCIS) of the breast is surgical resection, followed by radiation. Here, we tested localized therapy of DCIS in mice using the immunoconjugate 225Ac linked-trastuzumab delivered through the intraductal (i.duc) route. Trastuzumab targets HER-2/neu, while the alpha-emitter 225Ac (half-life, 10 days) delivers highly cytotoxic, focused doses of radiation to tumors. Systemic 225Ac, however, elicits hematologic toxicity and at high doses free 213Bi, generated by its decay, causes renal toxicity. I.duc delivery of the radioimmunoconjugate could bypass its systemic toxicity. Bioluminescent imaging showed that the therapeutic efficacy of intraductal 225Ac-trastuzumab (10-40 nCi per mammary gland; 30-120 nCi per mouse) in a DCIS model of human SUM225 cancer cells in NSG mice was significantly higher (p<0.0003) than intravenous (120 nCi per mouse) administration, with no kidney toxicity or loss of body weight. Our findings suggest that i.duc radioimmunotherapy using 225Ac-trastuzumab deserves greater attention for future clinical development as a treatment modality for early breast cancer.
JRC Directorate:Nuclear Safety and Security

Files in This Item:
There are no files associated with this item.


Items in repository are protected by copyright, with all rights reserved, unless otherwise indicated.